Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose safety and PK study of oral CORT113176 in healthy volunteers
NL-OMON51110Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of dazucorilant in amyotrophic lateral sclerosis (ALS) (6 arms), sponsored by Corcept Therapeutics. Primary endpoints: Safety, Pharmacokinetics in plasma and 1 more. Started Jul 2021; status: completed.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON51110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51110.